

Prognostic Value of Inflammatory Cytokines in Predicting Hospital Readmissions in Heart Failure with Preserved Ejection Fraction

Zhihao Zhao^{1,*}, Diya Qi^{1,*}, Zeqing Zhang^{2,*}, Xin Du³, Fengyun Zhang², Ruicong Ma⁴, Yi Liang¹, Yewu Zhao¹, Ying Gao¹, Yu Yang²

¹Department of Cardiology, the Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou First People's Hospital, Xuzhou, People's Republic of China; ²Department of Cardiology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, People's Republic of China; ³Department of Neurology, the Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou First People's Hospital, Xuzhou, People's Republic of China; ⁴Graduate School, Dalian Medical University, Dalian, People's Republic of China

*These authors contributed equally to this work

Correspondence: Ying Gao, Department of Cardiology, the Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou First People's Hospital, Xuzhou, People's Republic of China, Tel +86-13951461302, Email xzyygaoying@163.com; Yu Yang, Department of Cardiology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, People's Republic of China, Tel +86-15651359875, Email xuzhouyangyu@163.com

Purpose: The aim of this study was to explore the relationship between inflammatory cytokines and the risk of heart failure (HF) readmission in patients with heart failure with preserved ejection fraction (HFpEF).

Patients and Methods: We enrolled 429 patients with HFpEF admitted to the cardiology department in our hospital from January 2020 to July 2022. The patients were divided into the readmission or non-readmission groups according to whether they were readmitted for heart failure within 1 year of discharge. The clinical features and laboratory data of the subjects were collected and analyzed. Multivariate cox regression analysis was used to identify predictors of HF readmission. In addition, receiver operating characteristic (ROC) curves were used to determine the prognostic value of each factor.

Results: The levels of IL-1 β , IL-6, IL-10, IL-17, TNF- α , NT-proBNP, heart rate, total cholesterol and NYHA class were significantly higher in the readmission group than in the non-readmission group ($p < 0.05$). IL-1 β , IL-6, IL-17, TNF- α , NT-proBNP, heart rate and NYHA class were identified as independent predictors of HF readmission.

Conclusion: Inflammatory markers, including IL-1 β , IL-6, IL-17 and TNF- α were related to the HF readmission in patients with HFpEF.

Keywords: heart failure with preserved ejection fraction, inflammation, cytokine, readmission, risk assessment

Introduction

Heart failure (HF) is an advanced and terminal stage of various heart diseases.¹ It has a serious impact on patients' quality of life, increases hospitalization and mortality rates, and places a heavy economic burden on families and society.² The incidence of heart failure with preserved ejection fraction (HFpEF) has increased in recent years.³ Management of HFpEF and prevention of heart failure progression is critical, as treatment options for HFpEF remain limited.⁴

Previous studies showed that there was a close relationship between repeated readmissions and the decline in physical status in patients with HF.⁵ Also, it affected the patient's treatment compliance and led to the decline of cardiac function.⁶ Therefore, accurate assessment of patients' risk of readmission within 1 year is essential for early detection and intervention of disease and improve the prognosis of patients.

Chronic inflammation plays a vital role in the progression of HFpEF.⁷ This chronic inflammatory state can lead to adverse cardiac remodeling and eventually heart failure.⁸ It has been demonstrated that there was a strong association

between various cytokines and HF.⁹ However, only a few studies have investigated the association between cytokines and the risk of readmission in patients with heart failure with preserved ejection fraction within 1 year.

The purpose of this study was to determine whether the expression of 12 cytokines [IL-1 β , IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-17, interferon (IFN)- α , interferon (IFN)- γ , and tumor necrosis factor(TNF)- α] was differential in readmission group and non-readmission group in patients with HFpEF and whether they can be adopted to facilitate the early detection and intervention of disease in patients with HFpEF and improve the prognosis of patients.

Materials and Methods

Study Population

This retrospective study was based on the database of the Department of Cardiovascular Medicine, The Affiliated Municipal Hospital of Xuzhou Medical University from January 2020 to July 2022. The flow chart of our study was shown in Figure 1. Patients with HFpEF who survived to discharge at 1 year were included in our study. The main exclusion criteria were as follows: (1) patients lost to follow-up; (2) patients with recent infection; (3) severe valvular heart diseases; (4) hepatic or renal dysfunction; (5) hematological system diseases or autoimmune diseases; (6) a history of tumor.

Clinical Data Collection

The demographic and clinical characteristics of each patient were recorded at the beginning of first hospitalization, including age, gender, height, weight, body mass index (BMI), NYHA class, comorbidities, discharge medication usage, heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP) were collected from the electronic medical record system of the hospital by trained physicians who were blinded to the aim of the study. Laboratory data were obtained including white blood cells (WBC), high sensitivity-C reactive protein (hs-CRP), potassium, sodium, fasting blood glucose (FBG), creatinine, albumin, triglycerides, total cholesterol, low density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), glycosylated hemoglobin (HbA1c), serum creatinine, estimated glomerular filtration rate (eGFR), N-terminal-pro brain natriuretic peptide (NT-proBNP), left atrial diameter (LAD), left ventricular diameter (LVD), left ventricular ejection fraction (LVEF). Also, serum cytokines (IL-1 β , IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-17, IFN- α , IFN- γ , and TNF- α) were included. Inflammatory cytokines were assessed using flow cytometry and the Pylon 3D automated immunoassay system (ET Healthcare) in our hospital. HFpEF is defined as symptoms and signs of HF with left ventricular ejection fraction (LVEF) $\geq 50\%$, usually accompanied by structural or




Figure 1 Flow chart of our study.

Abbreviation: HFpEF, heart failure with preserved ejection fraction.

functional heart abnormalities such as left ventricular hypertrophy, left atrial enlargement, diastolic dysfunction or elevated natriuretic peptides.¹⁰ The endpoint of the study was defined as HF readmission within 1 year after hospital discharge.

Follow Up

All enrolled patients were followed-up regularly in the outpatient clinic or by remote telephone conversations with patients or family members. The follow-up continued for one year. Patients were divided into readmission and non-readmission groups based on whether they were readmitted because of HF within 1 year.

Statistical Analysis

All analyses were performed using SPSS version 25.0 (SPSS, Chicago, IL, USA), Stata version 13.0 and R version 4.0.3. Categorical variables were shown as rates (%) and continuous variables were expressed as mean standard deviation or median and interquartile range. The *t*-test was used to compare two groups, and one-way analysis of variance was used to compare three or more groups among numerical data with normal distribution. The Mann–Whitney *U*-test was used for quantitative data with non-normally distributed variables to compare between two groups and the Kruskal–Wallis test was used to compare between three or more groups. Cox regression analysis model was performed to assess the risk factors involved in the HF readmission in patients with HFpEF. The area under the curve (AUC) was used to evaluate the predictive value of each factor. Meanwhile, the AUC was calculated and compared by De-Long’s test to evaluate whether introducing the cytokines into the model of established risk factors could improve the predictive value. Additionally, net reclassification improvement (NRI) and integrated discrimination improvement (IDI) were also calculated to further evaluate the incremental predictive value of the cytokines. *P*-value <0.05 was considered statistically significant.

Results

The Baseline Data of Patients

In this study, a total of 429 patients with HFpEF were included in our hospital from January 2020 to July 2022. The demographic and clinical characteristics of the study population are shown in [Table 1](#).

A mean age of the participants was 79 (68, 84) years and 222 (51.7%) patients were male. Among these patients, 142 patients (33.1%) smoked, 100 patients (23.3%) drank, 155 patients (36.1%) developed hypertension, and 148 patients (34.5%) suffered from diabetes mellitus. There were significant differences between the readmission group and non-readmission group in terms of NT-proBNP, heart rate, total cholesterol, and NYHA class ($p < 0.05$).

Serum Cytokines Levels Under Different Groups

As is shown in [Figure 2](#), The levels of IL-1 β , IL-6, IL-10, IL-17 and TNF- α were significantly higher in the readmission group than in the non-readmission group ($p < 0.05$). Based on the NYHA class, patients were divided into three groups: NYHA II ($n = 70$), NYHA III ($n = 271$), and NYHA IV ($n = 88$). There was a significant difference in IL-1 β , IL-6, IL-10, IL-17, TNF- α levels based on the NYHA class ([Figure 3](#)). IL-1 β , IL-6, IL-17 and TNF- α levels in the NYHA IV group were significantly higher than in the NYHA II group ($p < 0.05$). Compared to the NYHA III group, IL-1 β , IL-6, IL-10, IL-17, and TNF- α levels were significantly higher in the NYHA IV group ($p < 0.05$).

Cox Regression Analysis of Readmission in Patients with HFpEF

Cox regression analysis was used to further assess the independent predictors of readmission in HFpEF. As shown in [Table 2](#), the results of the univariate cox regression analysis suggested that NYHA class, heart rate, total cholesterol, NT-proBNP, IL-1 β , IL-6, IL-10, IL-17 and TNF- α were associated with HF readmission. In multivariable cox regression models, NT-proBNP, heart rate, the levels of IL-1 β , IL-6, IL-17 and TNF- α were analyzed as the independent factors of HF readmission.

Table I Clinical Characteristics of Patients

| Variables | Total (n = 429) | Non-Readmission (n = 303) | Readmission (n = 126) | P-value |
|----------------------------|--------------------|------------------------------|--------------------------|---------|
| Age (years) | 79 (68, 84) | 76 (69, 84) | 75 (66, 85) | 0.123 |
| Gender, n (%) | | | | 0.458 |
| Male | 222 (51.7) | 153 (50.5) | 69 (54.8) | |
| Female | 207 (48.3) | 150 (49.5) | 57 (45.2) | |
| Height (m) | 1.65 (1.60, 1.70) | 1.64 (1.60, 1.70) | 1.65 (1.60, 1.70) | 0.523 |
| Weight (kg) | 62 (55, 72) | 62 (55, 72) | 62 (55, 70) | 0.488 |
| BMI (kg/m ²) | 23.2 (20, 26.6) | 23.4 (20, 26.6) | 22.6 (20.1, 26.2) | 0.208 |
| Heart rate (b.p.m.) | 75 (66, 87) | 75 (65, 85) | 80 (70, 94) | 0.001 |
| SBP (mmHg) | 130 (114, 148) | 130 (114.5, 148) | 126.5 (111, 142) | 0.208 |
| DBP (mmHg) | 74 (68, 80) | 74 (68, 80.5) | 74 (68, 80) | 0.945 |
| NYHA class, n (%) | | | | 0.003 |
| II | 70 (16.3) | 58 (19.1) | 12 (9.5) | |
| III | 271 (63.2) | 194 (64.0) | 77 (61.1) | |
| IV | 88 (20.5) | 51 (16.8) | 37 (29.4) | |
| Comorbidity | | | | |
| CAD, n (%) | 245 (57.1) | 168 (55.4) | 77 (61.1) | 0.331 |
| Atrial fibrillation, n (%) | 154 (35.9) | 107 (35.3) | 47 (37.3) | 0.696 |
| Diabetes, n (%) | 148 (34.5) | 107 (35.3) | 41 (32.5) | 0.661 |
| Hypertension, n (%) | 155 (36.1) | 107 (35.3) | 48 (38.1) | 0.663 |
| Stroke, n (%) | 64 (14.9) | 49 (16.2) | 15 (11.9) | 0.327 |
| COPD, n (%) | 43 (10.0) | 33 (10.9) | 10 (7.9) | 0.452 |
| Smoking, n (%) | 142 (33.1) | 103 (34.0) | 39 (31.0) | 0.619 |
| Drinking, n (%) | 100 (23.3) | 72 (23.8) | 28 (22.2) | 0.827 |
| ACEI/ARB, n (%) | 274 (63.9) | 194 (64) | 80 (63.5) | 0.916 |
| β-blocker, n (%) | 271 (63.2) | 186 (61.4) | 85 (67.5) | 0.281 |
| CCB, n (%) | 85 (19.8) | 55 (18.2) | 30 (23.8) | 0.228 |
| Statin, n (%) | 288 (67.1) | 206 (68) | 82 (65.1) | 0.638 |
| Digitalis, n (%) | 86 (20.0) | 62 (20.5) | 24 (19.0) | 0.841 |
| Diuretic, n (%) | 304 (70.9) | 220 (72.6) | 84 (66.7) | 0.264 |
| Imaging index | | | | |
| LAD (mm) | 41 (37, 48) | 41 (36, 49) | 41 (39, 47) | 0.261 |
| LVD (mm) | 50 (44, 58) | 50 (44, 57) | 50 (44, 58) | 0.790 |
| LVEF, n (%) | 58 (55, 60) | 58 (55, 60) | 57 (54, 60) | 0.104 |

(Continued)

Table 1 (Continued).

| Variables | Total (n = 429) | Non-Readmission (n = 303) | Readmission (n = 126) | P-value |
|--|--------------------|------------------------------|--------------------------|---------|
| Laboratory index | | | | |
| WBC ($\times 10^9/L$) | 5.8 (4.4, 7.2) | 5.8 (4.3, 7) | 5.8 (4.5, 7.4) | 0.617 |
| hs-CRP (mg/L) | 2.6 (1.3, 10.2) | 2.6 (1.2, 10.2) | 2.6 (1.4, 10.6) | 0.665 |
| HbA1c (%) | 6.2 (5.9, 6.8) | 6.2 (5.9, 6.8) | 6.4 (5.9, 7) | 0.238 |
| NT-proBNP (pg/mL) | 800 (248, 1347) | 547 (224.5, 1241) | 959 (378, 2006) | < 0.001 |
| Albumin (g/L) | 37.8 (33.8, 40.3) | 37.8 (33.8, 39.8) | 38.3 (33.5, 40.9) | 0.285 |
| Serum creatinine ($\mu\text{mol/L}$) | 77 (61, 96) | 77 (61, 95) | 77 (61, 103.2) | 0.598 |
| Blood glucose (mmol/L) | 6.3 (5.2, 7.4) | 6.4 (5.3, 7.4) | 6.3 (5.2, 7.7) | 0.885 |
| Serum sodium (mmol/L) | 138 (135, 141) | 138 (134, 141) | 139 (136, 141) | 0.063 |
| Serum kalium (mmol/L) | 4 (3.7, 4.2) | 4 (3.6, 4.2) | 4 (3.7, 4.3) | 0.375 |
| eGFR ($\text{mL}/\text{min} \times 1.73\text{m}^{-2}$) | 84.1 (65.3, 103.8) | 85.8 (68.4, 104) | 81.7 (58.5, 102.1) | 0.115 |
| Total cholesterol (mmol/L) | 3.6 (2.9, 4.4) | 3.6 (2.7, 4.3) | 3.7 (2.9, 4.6) | 0.008 |
| Triglyceride (mmol/L) | 1 (0.7, 1.4) | 1 (0.7, 1.3) | 1 (0.6, 1.6) | 0.282 |
| HDL-C (mmol/L) | 1.1 (0.9, 1.4) | 1.1 (0.9, 1.4) | 1.2 (0.9, 1.5) | 0.111 |
| LDL-C (mmol/L) | 1.9 (1.4, 2.6) | 1.9 (1.4, 2.6) | 2 (1.5, 2.6) | 0.285 |
| Inflammatory Cytokines | | | | |
| IL-1 β (pg/mL) | 6.6 (6.4, 9.4) | 6.5 (6.2, 7.8) | 8.0 (6.6, 14.4) | < 0.001 |
| IL-2 (pg/mL) | 1.1 (0.4, 1.6) | 1.1 (0.4, 1.5) | 1.1 (0.7, 1.7) | 0.082 |
| IL-4 (pg/mL) | 0.9 (0.5, 1.4) | 0.8 (0.5, 1.5) | 0.9 (0.5, 1.2) | 0.222 |
| IL-5 (pg/mL) | 1.8 (1.2, 3.4) | 1.9 (1.2, 3.2) | 1.8 (1.2, 4.0) | 0.358 |
| IL-6 (pg/mL) | 3.5 (1.9, 6.3) | 2.8 (1.8, 5.8) | 5.0 (2.6, 13.3) | < 0.001 |
| IL-8 (pg/mL) | 2.8 (1.9, 5.2) | 2.6 (1.9, 4.3) | 2.8 (2.1, 7.8) | 0.135 |
| IL-10 (pg/mL) | 1.1 (0.9, 1.8) | 1.1 (0.9, 1.6) | 1.3 (0.9, 2.4) | 0.008 |
| IL-12p70 (pg/mL) | 1 (0.9, 1.4) | 1 (0.9, 1.2) | 1.1 (0.9, 1.6) | 0.103 |
| IL-17 (pg/mL) | 1.4 (0.9, 2.4) | 1.2 (0.8, 2) | 2.0 (1.1, 6.4) | < 0.001 |
| IFN- α (pg/mL) | 1.2 (0.6, 2.3) | 1.2 (0.6, 2.2) | 1.4 (0.8, 2.4) | 0.059 |
| IFN- γ (pg/mL) | 5.4 (3.1, 8.5) | 5.2 (3.2, 7.6) | 5.9 (3, 11.1) | 0.059 |
| TNF- α (pg/mL) | 2.1 (1.9, 3.1) | 2.1 (1.7, 2.6) | 2.7 (2, 4.3) | < 0.001 |

Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CCB, calcium channel blocker; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor inhibitor; WBC, white blood cell count; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NT-proBNP: N-terminal-pro brain natriuretic peptide; HbA1c, glycosylated hemoglobin; LVEF, left ventricular ejection fraction; LAD, left atrial diameter; LVD, left ventricular diameter; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; ARNI, angiotensin receptor neprilysin inhibitors; IL-1 β , interleukin-1 β ; IL-2, interleukin-2; IL-4, interleukin-4; IL-5, interleukin-5; IL-6, interleukin-6; IL-8, interleukin-8; IL-10, interleukin-10; IL-12p70, interleukin-12p70; IL-17, interleukin-17; IFN- α , interferon-alpha; IFN- γ , interferon-gamma; TNF- α , tumor necrosis factor-alpha.




Figure 2 Prognosis of inflammatory cytokines in HF patients. Levels of IL-1 β (A), IL-6(B), IL-10(C), IL-17(D) and TNF- α (E) in readmission and non-readmission patients of HF patients. ** $p < 0.01$, *** $p < 0.001$.

Abbreviations: HF, heart failure; IL-1 β , interleukin-1 β ; IL-6, interleukin-6; IL-10, interleukin-10; IL-17, interleukin-17; TNF- α , tumor necrosis factor-alpha.

Receiver Operating Characteristic Curve Analysis of Cytokines in Predicting HF Readmission in Patients with HFpEF

As shown in Figure 4, the Area Under Curve (AUC) for IL-1 β , IL-6, IL-17 and TNF- α to predict HF readmission were 0.740 (95% CI: 0.691–0.788, $p < 0.001$), 0.646 (95% CI: 0.588–0.705, $p < 0.001$), 0.693 (95% CI: 0.637–0.748, $p < 0.001$) and 0.730 (95% CI: 0.650–0.759, $p < 0.001$), and cut-off were 6.6, 6.3, 5.3, and 6.7 respectively. It is demonstrated that IL-1 β showed the best predictive value among cytokines. Meanwhile, the AUC obtained from the model of established risk factors, which consisted of heart rate, NYHA class, and NT-proBNP, was 0.743 (95% CI: 0.690–0.797, $p < 0.001$). Furthermore, adding the IL-1 β to the model of established risk factors could lead to an increase in AUC (0.790 [95% CI: 0.741–0.839] vs 0.743 [95% CI: 0.690–0.797], $p = 0.001$), NRI (0.540 [0.349–0.731], $p < 0.001$), and IDI (0.072[0.040–0.104], $p < 0.001$) (Figure 4).

Discussion

This study mainly assessed the relationships between serum levels of 12 cytokines and HF readmission in patients with HFpEF. The results show that the cytokines IL-1 β , IL-6, IL-17 and TNF- α were higher readmission groups than non-readmission groups in patients with HFpEF. Also, Serum cytokines levels included IL-1 β , IL-6, IL-17 and TNF- α was different under three NYHA class groups.




Figure 3 Levels of IL-1 β (A), IL-6(B), IL-10(C), IL-17(D) and TNF- α (E) in HFpEF patients based on the NYHA class. * $p < 0.05$, ** $p < 0.01$.

Abbreviations: HFpEF, heart failure with preserved ejection fraction; IL-1 β , interleukin-1 β ; IL-6, interleukin-6; IL-10, interleukin-10; IL-17, interleukin-17; TNF- α , tumor necrosis factor-alpha.

With the increasing age of the population and the rise in cardiovascular disease and its risk factors, the incidence of heart failure in the elderly is expected to continue to rise in the future.¹¹ Approximately half of patients with heart failure develop heart failure with preserved ejection fraction (HFpEF).¹² HFpEF causes huge economic burden to society and family because of repeated hospitalization.¹³ Despite extensive research in recent decades, HFpEF treatment options are few and it remains a global health problem.

Table 2 Cox Regression Analysis of Readmission Within 1 Year Among HF Patients

| Variables | Univariate Analysis HR (95% CI) | P value | Multivariate Analysis HR (95% CI) | P value |
|-------------------|------------------------------------|---------|--------------------------------------|---------|
| Heart rate | 1.015(1.006–1.023) | 0.001 | 1.016 (1.007–1.025) | 0.001 |
| NYHA class | 1.795(1.338–2.408) | 0.001 | 1.519(1.107–2.085) | 0.010 |
| Total cholesterol | 1.186(1.002–1.403) | 0.047 | 1.088(0.906–1.307) | 0.366 |
| NT-proBNP | 1.022(1.017–1.027) | 0.001 | 1.021(1.015–1.027) | 0.001 |
| IL-1 β | 1.079(1.060–1.099) | <0.001 | 1.055(1.022–1.090) | 0.001 |
| IL-6 | 1.039(1.028–1.050) | <0.001 | 1.019(1.005–1.032) | 0.008 |
| IL-10 | 1.183(1.104–1.267) | 0.001 | 0.908(0.799–1.032) | 0.139 |
| IL-17 | 1.174(1.138–1.211) | <0.001 | 1.066(1.020–1.113) | 0.004 |
| TNF- α | 1.110(1.084–1.137) | <0.001 | 1.047 (1.010–1.085) | 0.013 |

Abbreviations: NT-proBNP, N-terminal-pro brain natriuretic peptide; IL-1 β , interleukin-1 β ; IL-6, interleukin-6; IL-10, interleukin-10; IL-17, interleukin-17; TNF- α , tumor necrosis factor-alpha.




Figure 4 ROC curves of IL-1 β , IL-6, IL-17 and TNF- α showing different abilities to predict HF readmission (A) and comparison of the AUC between the models (B). **Abbreviations:** ROC, Receiver operating characteristic; HF, heart failure, IL-1 β , interleukin-1 β ; IL-6, interleukin-6; IL-17, interleukin-17; TNF- α , tumor necrosis factor- α .

The relationship between inflammation and heart failure has become a hot research topic in recent years.¹⁴ This chronic inflammatory state can lead to adverse cardiac remodeling, such as left ventricular hypertrophy, ultimately leading to HFpEF.¹⁵ Inflammation also appears to be more common in HFpEF compared with HFrEF in studies, which may suggest a different pathophysiology.^{16,17} This study may provide new inspiration for the clinical treatment of HFpEF.

The level of serum cytokines is often used to reflect the body's inflammatory state and inflammatory response bias.^{18,19} It has been shown that cardiovascular disease was closely related to cytokines. Several studies have uncovered an association between CAD and cytokines.²⁰ In addition, the synthesis of cytokine-induced growth factors may have a chronic fibrogenic effect that contributes to the pathogenesis of heart failure with preserved ejection fraction (HFpEF).^{21,22}

In our study, serum IL-1 β , IL-6, IL-17, and TNF- α levels increased in readmission groups. Interestingly, the level of IL-1 β , IL-6, IL-17, and TNF- α increase as grades of NYHA class. The interleukin-1 family of cytokines is a group of classical inflammatory factors. They are involved in the onset and development of many fibrotic diseases.²³ Also, Interleukin-1 is involved in pathogenic pathways and is a therapeutic target for inflammation in heart disease.²⁴ Interleukin-1 β (IL-1 β) is a pro-inflammatory cytokine that has been suggested to be involved in cardiac remodelling after ischaemia and impairment in ventricular contractility and relaxation.^{25,26} IL-6 initiates the leucocyte infiltration. Persistent inflammation can lead to a destructive tissue reaction that causes tissue fibrosis. Individuals with elevated IL-6 levels have a higher risk of heart failure compared to those without a history of cardiovascular disease.²⁷ IL-17 enhanced the release of pro-inflammatory cytokines including IL-1 and IL-6.^{28,29} Patients with higher levels of IL-17 were more likely to have atrial fibrillation (AF), kidney dysfunction and heart failure with preserved ejection fraction (HFpEF).^{30,31} TNF- α has been shown to play a specific role in patients with HFpEF compared with HFrEF and controls, correlating with myocardial fibrosis and stiffening.^{32,33} Consistent with previous studies, HFpEF patients with higher level of NT-proBNP, heart rate and NYHA class has a higher incidence of HF admission.^{34,35}

Limitations

This was a single-centre trial, so there may have been a selection bias in the patients enrolled; We did not monitor dynamic changes in cytokines during the study period. Further prospective studies based on multicentre and large sample sizes are needed to verify our conclusions.

Conclusion

In summary, this study showed the inflammatory markers, IL-1 β , IL-6, IL-17, and TNF- α , could be adopted to predict the HF readmission in patients with HFpEF, which may become potential therapeutic targets for clinical use in the future.

Ethics Statement

This study was designed in accordance with the Declaration of Helsinki and approved by the ethics committee of the Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University. Due to the study being a retrospective analysis, the review committee waived the requirement for written informed consent. Confidential patient information was removed from the entire data set prior to analysis.

Acknowledgments

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Joseph P, Roy A, Lonn E, et al. Global variations in heart failure etiology, management, and outcomes. *JAMA*. 2023;329(19):1650–1661. doi:10.1001/jama.2023.5942
2. Metra M, Tomasoni D, Adamo M, et al. Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the heart failure association of the European society of cardiology. *Eur J Heart Fail*. 2023;25(6):776–791. doi:10.1002/ejhf.2874
3. MacDonald BJ, Virani SA, Zieroth S, et al. Heart failure management in 2023: a pharmacotherapy- and lifestyle-focused comparison of current international guidelines. *CJC Open*. 2023;5(8):629–640. doi:10.1016/j.cjco.2023.05.008
4. Desai AS, Lam C, McMurray J, et al. How to manage heart failure with preserved ejection fraction: practical guidance for clinicians. *JACC Heart Fail*. 2023;11(6):619–636. doi:10.1016/j.jchf.2023.03.011
5. Gheorghiadu M, Follath F, Ponikowski P, et al. Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European society of intensive care medicine. *Eur J Heart Fail*. 2010;12(5):423–433. doi:10.1093/eurjhf/hfq045
6. Nolan M, Arnott C. Risks and burdens of unplanned heart failure readmissions: how to cut a Gordian knot? *Heart Lung Circ*. 2023;32(8):891–893. doi:10.1016/j.hlc.2023.08.002
7. Peh ZH, Dihoum A, Hutton D, et al. Inflammation as a therapeutic target in heart failure with preserved ejection fraction. *Front Cardiovasc Med*. 2023;10:1125687. doi:10.3389/fcvm.2023.1125687
8. Mooney L, Jackson CE, Adamson C, et al. Adverse outcomes associated with interleukin-6 in patients recently hospitalized for heart failure with preserved ejection fraction. *Circ Heart Fail*. 2023;16(4):e010051. doi:10.1161/CIRCHEARTFAILURE.122.010051
9. Segiet OA, Piecuch A, Mielanczyk L, et al. Role of interleukins in heart failure with reduced ejection fraction. *Anatol J Cardiol*. 2019;22(6):287–299. doi:10.14744/AnatolJCardiol.2019.32748
10. McDonagh TA, Metra M, Adamo M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*. 2023;44(37):3627–3639. doi:10.1093/eurheartj/ehad195
11. Chen Y, Zheng H, He Y. Prognostic significance of controlling nutritional status in older adults with heart failure with preserved ejection fraction: a prospective comparative study with other objective nutritional indices. *Aging Clin Exp Res*. 2023;35(6):1305–1315. doi:10.1007/s40520-023-02395-x
12. Zhou Q, Yang J, Tang H, et al. High triglyceride-glucose (TyG) index is associated with poor prognosis of heart failure with preserved ejection fraction. *Cardiovasc Diabetol*. 2023;22(1):263. doi:10.1186/s12933-023-02001-4
13. Rego R, Pereira N, Pinto A, et al. Impact of a heart failure multidisciplinary clinic on the reduction of healthcare-related events and costs: the GEstIC study. *Front Cardiovasc Med*. 2023;10:1232291. doi:10.3389/fcvm.2023.1232291
14. Sotomi Y, Tamaki S, Hikoso S, et al. Pathophysiological insights into machine learning-based subphenotypes of acute heart failure with preserved ejection fraction. *Heart*. 2023. doi:10.1136/heartjnl-2023-323059
15. Ye B, Bradshaw AD, Abraham JE, et al. Left ventricular gene expression in heart failure with preserved ejection fraction—proinflammatory and profibrotic pathways and genes. *Circ Heart Fail*. 2023;16(8):e010395. doi:10.1161/CIRCHEARTFAILURE.123.010395
16. Paulus WJ. Unfolding Discoveries in Heart Failure. *N Engl J Med*. 2020;382(7):679–682. doi:10.1056/NEJMcibr1913825
17. Riehle C, Bauersachs J. Key inflammatory mechanisms underlying heart failure. *Herz*. 2019;44(2):96–106. doi:10.1007/s00059-019-4785-8
18. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. *Physiol Rev*. 2006;86(2):515–581. doi:10.1152/physrev.00024.2005
19. Tsioufis P, Theofilis P, Tsioufis K, et al. The impact of cytokines in coronary atherosclerotic plaque: current therapeutic approaches. *Int J Mol Sci*. 2022;23(24):15937. doi:10.3390/ijms232415937

20. Liu S, Ni S, Wang C, et al. Association of serum cytokines with coronary chronic total occlusion and their role in predicting procedural outcomes. *Hellenic J Cardiol.* 2023. doi:10.1016/j.hjc.2023.08.013
21. Schiattarella GG, Rodolico D, Hill JA. Metabolic inflammation in heart failure with preserved ejection fraction. *Cardiovasc Res.* 2021;117(2):423–434. doi:10.1093/cvr/cvaa217
22. Schiattarella GG, Alcaide P, Condorelli G, et al. Immunometabolic Mechanisms of heart failure with preserved ejection fraction. *Nat Cardiovasc Res.* 2022;1(3):211–222. doi:10.1038/s44161-022-00032-w
23. Wang H, Wu J, Ma L, et al. The role of interleukin –1 family in fibrotic diseases. *Cytokine.* 2023;165:156161. doi:10.1016/j.cyto.2023.156161
24. Del Buono MG, Bonaventura A, Vecchié A, et al. Pathogenic pathways and therapeutic targets of inflammation in heart diseases: a focus on Interleukin-1. *Eur J Clin Invest.* 2023. doi:10.1111/eci.14110
25. Abbate A, Toldo S, Marchetti C, et al. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease. *Circ Res.* 2020;126(9):1260–1280. doi:10.1161/CIRCRESAHA.120.315937
26. Liu H, Huang Y, Zhao Y, et al. Inflammatory macrophage interleukin-1 β mediates high-fat diet-induced heart failure with preserved ejection fraction. *JACC Basic Transl Sci.* 2023;8(2):174–185. doi:10.1016/j.jacpts.2022.08.003
27. Alogna A, Koepp KE, Sabbah M, et al. Interleukin-6 in patients with heart failure and preserved ejection fraction. *JACC Heart Fail.* 2023. doi:10.1016/j.jchf.2023.06.031
28. Sandip C, Tan L, Huang J, et al. Common variants in IL-17A/IL-17RA axis contribute to predisposition to and progression of congestive heart failure. *Medicine.* 2016;95(27):e4105. doi:10.1097/MD.0000000000004105
29. Baldeviano GC, Barin JG, Talor MV, et al. Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy. *Circ Res.* 2010;106(10):1646–1655. doi:10.1161/CIRCRESAHA.109.213157
30. Li XF, Pan D, Zhang WL, et al. Association of NT-proBNP and interleukin-17 levels with heart failure in elderly patients. *Genet Mol Res.* 2016;15(2). doi:10.4238/gmr.15028014
31. Baumhove L, Bomer N, Tromp J, et al. Clinical characteristics and prognosis of patients with heart failure and high concentrations of interleukin-17D. *Int J Cardiol.* 2023;131384. doi:10.1016/j.ijcard.2023.131384
32. Manilall A, Mokotedi L, Gunter S, et al. Tumor necrosis factor- α mediates inflammation-induced early-stage left ventricular systolic dysfunction. *J Cardiovasc Pharmacol.* 2023;81(6):411–422. doi:10.1097/FJC.0000000000001428
33. Albar Z, Albakri M, Hajjari J, et al. Inflammatory markers and risk of heart failure with reduced to preserved ejection fraction. *Am J Cardiol.* 2022;167:68–75. doi:10.1016/j.amjcard.2021.11.045
34. Chan MM, Santhanakrishnan R, Chong JP, et al. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction. *Eur J Heart Fail.* 2016;18(1):81–88. doi:10.1002/ejhf.431
35. Wang S, Wang Y, Luo M, et al. MMEELD-XI score is associated with short-term adverse events in patients with heart failure with preserved ejection fraction. *Front Cardiovasc Med.* 2021;8:650191. doi:10.3389/fcvm.2021.650191

Journal of Inflammation Research

Dovepress

Publish your work in this journal

The Journal of Inflammation Research is an international, peer-reviewed open-access journal that welcomes laboratory and clinical findings on the molecular basis, cell biology and pharmacology of inflammation including original research, reviews, symposium reports, hypothesis formation and commentaries on: acute/chronic inflammation; mediators of inflammation; cellular processes; molecular mechanisms; pharmacology and novel anti-inflammatory drugs; clinical conditions involving inflammation. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/journal-of-inflammation-research-journal>